elobixibat   Click here for help

GtoPdb Ligand ID: 9996

Synonyms: 2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1λ6,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic acid | A3309 | AJG533 | AZD-7806 | AZD7806 | Goofice®
Approved drug
elobixibat is an approved drug (Japan (2018))
Compound class: Synthetic organic
Comment: Elobixibat is an orally available inhibitor of the ileal bile acid transporter (IBAT or ASBT), which is the protein product of the SLC10A2 gene. It is being evaluated for clinical utility in the management of chronic constipation [1,3,6]. The chemical structure is claimed as Example 14 in Albireo Ab's patent US20130225511A1 [2] (we have chosen this iteration of the patent as it has both chemical structure images and data included in online versions).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 18
Topological polar surface area 175.79
Molecular weight 695.27
XLogP 7.58
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCCC1(CCCC)CN(c2ccccc2)c2c(S(=O)(=O)C1)cc(c(c2)SC)OCC(=O)NC(c1ccccc1)C(=O)NCC(=O)O
Isomeric SMILES CCCCC1(CCCC)CN(c2ccccc2)c2c(S(=O)(=O)C1)cc(c(c2)SC)OCC(=O)N[C@H](c1ccccc1)C(=O)NCC(=O)O
InChI InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1
InChI Key XFLQIRAKKLNXRQ-UUWRZZSWSA-N
No information available.
Summary of Clinical Use Click here for help
Elobixibat is approved in Japan (trade name Goofice®) for the treatment of chronic constipation. Phase 3 clinical trial results from Japanese studies are published in [4] and [5]. Elobixibat was found to be effective in resolving constipation and was well tolerated in the short- and long-term.
Elobixibat was also investiagted in nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), with the hypothesis being that ASBT inhibition might improve the liver damage (scarring and inflammation) and disordered levels of bile acids, fat and glucose, in these conditions.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Elobixibat increases intracolonic concentrations of endogenous bile acids and subsequently enhances colonic secretion and improves gut motility [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04235205 Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease Phase 2 Interventional Yokohama City University
NCT01038687 Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation Phase 2 Interventional Mayo Clinic
NCT04006145 A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Phase 2 Interventional Albireo Albireo terminated development of elobixibat for NASH and NAFLD, as no improvement in liver enzyme levels or reduction in liver fat that would suggest clinical benefit in NASH, was detected by this trial.